Tremelimumab AstraZeneca Európai Unió - magyar - EMA (European Medicines Agency)

tremelimumab astrazeneca

astrazeneca ab - tremelimumab - karcinóma, nem kissejtes tüdő - daganatellenes szerek - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Tevimbra Európai Unió - magyar - EMA (European Medicines Agency)

tevimbra

novartis europharm limited - tislelizumab - esophageal squamous cell carcinoma - daganatellenes szerek - oesophageal squamous cell carcinoma (oscc) tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy.